Cozaar drug 100mg MSD treats hypertension (3 blisters x 10 tablets)

Hypotension and electrolyte/epidemic imbalance:

Electrolyte imbalance:

Cuong Aldosteron Tien Phat:

coronary artery disease and cerebrovascular disease:

heart failure:

Aortic stenosis and narrow valve stenosis, hypertrophic cardiomyopathy:

Double inhibition of the renin-ankiotensin-aldosteron (RAAS):

Use for children:

Babies have a history of cozaar 100 exposure in the uterus:

If urinary or hypotension occurs, pay directly on blood pressure support and kidney perfusion.

may need to replace blood or fertilize as a measure to reverse hypotension and/or instead of kidney function.

The hypotension effect of Cozaar 100 in children from> 1 month to 16 years old with hypertension has been proven.

Using Cozaar 100 in these age groups has been strengthened by evidence from good and appropriate control studies on children and adults using Cozaar 100 as well as by literature about drug use in children.

Losartan's pharmacokinetic properties have been studied over 50 children from> 1 month to

Losartan's pharmacokinetic properties and metabolites are similarly active in age groups that are studied and suitable for the pharmacokinetics of the drug in adults.

In a clinical study, there are 177 patients from 6 to 16 years old with hypertension, children weigh from ≥ 20 kg to

Response the dose of Losartan is recorded in all subgroups (for example, age, puberty stages according to the tanner, gender, race). However, the lowest dose studied is 2.5 mg and 5 mg, corresponding to the daily dose daily 0.07 mg/kg, seems to not bring stable hypotension effect. In this study, Cozaar 100 is well tolerated.

For children who can swallow the tablet, the recommended dose is 25 mg once a day in patients severely ≥ 20 kg to 50kg, the starting dose is 50 mg, once a day. Can increase the dose to up to 100 mg, once a day.

On the patients, there is a decrease in the volume of circulating, it is necessary to adjust this condition before using Cozaar 100.

Harmful reactions occur in children when using the drug is similar to the observed reactions in adults.

Do not recommend the use of cozaar 100 in patients with glomerular filtration

Used for the elderly:

Race:

Based on the study of the effect of reducing blood pressure when intervention with Losartan (Losartan Intermedion for Endpoint Reduction in Hypertension (Life), the benefit reduces the incidence and mortality due to cardiovascular disease in patients with cozaar 100 compared to the atenolol group that cannot be applied to black skin hypertension patients with hypertension, both effectively wearing both black and hypertension on these two groups of black skin patients with these two groups of black and hyperplasia on the two groups of black black patients with these two groups of black and hyperplasia in these groups of black black skin patients with these groups of black skin patients with these groups of black skin patients with these groups. are the same.

For the general population of the Life study (n = 9.193), Cozaar 100 reduces 13.0% of risk (P = 0.021) compared to the use of Atenolol for the main criterion of coordinating cardiovascular death events, stroke and myocardial infarction.

In this study, Cozaar 100 reduced the risk of cardiovascular disease and cardiovascular death compared to the use of Atenolol for patients who are not in black racial groups, suffer from hypertension with left ventricular hypertrophy (n = 8,660), which are assessed by the main criteria for combination of cardiovascular deaths, stroke, myocardial infarction (P = 0.003). However, in this study, black skin patients treated with Atenolol are less likely to have more coordinated events than the group of black skin patients using Cozaar 100 (P = 0.03).

In the division of black skin patients (n = 533, accounting for 6%of the patient in Life study), there were 29 cases of 263 patients using Atenolol encountered this group of incidents (11%; 25.9 for each 1,000 patients-in-year) and 46 cases among 270 patients using COZAAR 100 (17%; 41.8 for each patient-patient).

The ability to drive and operate machinery

There is no research on impact on the ability to drive and operate machinery has been done. However, when driving or operating machinery, it is important to note that dizziness or drowsiness can sometimes occur when using anti -hypertension therapy, especially when starting treatment or when increasing the dose.

Pregnancy

Medicines directly acting on the Renin-Anotensin system can cause damage and developing pregnancy. When detected pregnancy, must stop cozaar 100 as soon as possible.

Although there is no experience in using Cozaar 100 for pregnant women, studies with Losartan Kali have shown that the injury in the fetus, babies, and death, the mechanism of this influence is thought to be due to the intermediate pharmacological properties that act on the Renin-Anotensin system.

In humans, the fetal kidney perfusion depends on the development of the renin-analiotensin system, starting in the middle of the middle of pregnancy, so the risk of the fetus increases if using COZAAR 100 in the middle of the middle or the last three months of pregnancy.

The use of drugs on the Renin-Anotensin system in the middle and the last three months of pregnancy reduces the kidney function of the fetus, increases disease and death in the fetus and infants.

The amniotic fluid results may be associated with reduced lung production and skeletal deformation in fetus. The possible side effects in newborns include reducing skull production, anuria, hypotension, renal failure and death. When detected pregnancy, must stop cozaar 100 as soon as possible.

These harmful results are often associated with the use of these drugs in the middle and the last three months of pregnancy. Most epidemiological studies survey abnormalities in fetuses after exposure to anti-hypertension drugs used in the first three months of pregnancy, regardless of drugs that affect the renin-angiotensin system with other anti-hypertension drugs. The appropriate management of hypertension in the mother during pregnancy is important to optimize the results for both mother and pregnancy.

In special cases when there is no appropriate replacement treatment for drug treatments that affect the renin-angiotensin system for a separate patient, must notify the mother about the risk that may occur for fetuses.

It is necessary to conduct a mass ultrasound test to assess the environment in the amniotic fluid. Stop using cozaar 100 if observed with amniotic fluid unless this drug is considered a medicine to save life for the mother. The pregnancy test may be appropriate, based on the week of gestational age.

However, doctors and patients should know that amniotic fluid may not show until the pregnancy has been damaged for prolonged irreversible.

Need to closely monitor babies with a history of cozaar exposure 100 in the uterus on manifestations of hypotension, urinary discharge and hyperkalemia.

The period of breastfeeding

It is unclear whether Losartan will be secreted into the mother's milk. Because many drugs are secreted into the mother's milk and due to the potential for adultery effects to breastfeed, decide or stop the drug or stop breastfeeding, consider the importance of the drug for the mother.

Interactive drug

other hypertension medications may increase the hypotension effect of Losartan. Concomitant use with other substances that can cause lower blood pressure as a adverse reaction (such as three -round antidepressants, anti -psychotic drugs, Baclofen and amifostin) can increase the risk of hypotension.

Losartan is mainly converted by Cytochrom P450 (CYP) 2C9 into active carboxy acid conversion. In a clinical trial, fluconazole (CYP2C9 inhibitors) has reduced the concentration of metabolites with an activity of about 50%.

What has been found is the simultaneous treatment of losartan with rifampicin (drug -induced drugs of metabolic enzymes) provides a 40% reduction in plasma metabolic concentration.

unclear clinical significance of this effect. The difference in concentration is not found with the concentration of simultaneous treatment with fluvastatin (weak inhibitor CYP2C9).

Like other drugs Angiotensin II blockers or its effects, simultaneous use with other drugs that keep potassium (for example, potassium diuretics: amilorid, triamteren, spironolacton) or may increase potassium levels (for example, heparin), potassium supplements or salt replacement substances that contain potassium can lead to hyperlemia. Do not use the drug simultaneously.

Increased lachium and toxic lithium concentration has been reported while using simultaneously lithium with enzyme inhibitors.

Very rare cases have also been reported to Angiotensin II receptor antagonists. The simultaneous use of Lithium and Losartan should be done carefully. If this combination proves to be necessary, the recommendation to monitor serum lithium concentration when used simultaneously.

When using Angiotensin II antagonist simultaneously with nonsteroidal anti-inflammatory drugs (NSAID) (i.e., COX-2 inhibitors, acetylsalicylic acid in anti-inflammatory doses and non-selective steroid anti-inflammatory doses), reduced hypotension may occur.

Concentrated Angiotensin II antagonistic drugs or non -steroid anti -inflammatory drugs can lead to an increased risk of kidney function, including acute renal failure that may be encountered and increased serum potassium, especially in patients with poor kidney function before.

Be careful when using this combination, especially in the elderly. It should be fully rehydrated for patients and should consider monitoring kidney function after starting treatment simultaneously and periodically later.

Clinical testing data has shown double-analotensin-aldosteron (RAAS) inhibitors by using a combination of enzyme inhibitors, Angiotensin II or Aliskiren receptor blockers that are more involved in adverse frequencies such as hypotension, hyperpoint of blood potassium and reduced kidney function (including acute renal impairment) compared to a effect Renin-Anotensin-Aldosteron.